Role of medication in the level of aluminium in the blood of chronic haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 4, 2009, Pages 1277-1281

  Bohrer, Denise ^a,b   Bertagnolli, Denise C ^a   De Oliveira, Sandra M R ^a   Do Nascimento, Paulo C ^a   De Carvalho, Leandro M ^a   Garcia, Solange C ^b   Arantes, Luiz C ^c   Barros, Elvino J G ^d  

^a Department of Chemistry ^*  (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c Hospital of the Federal University of Santa Maria   (United States)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Aluminium; Elevated serum aluminium; Erythropoietin; Insulin; Iron

Indexed keywords

ALUMINUM; CALCITRIOL; CALCIUM CARBONATE; CAPTOPRIL; CLONIDINE; DIGOXIN; ENALAPRIL; ERYTHROPOIETIN; FUROSEMIDE; INSULIN; IRON; NIFEDIPINE; PROPRANOLOL DERIVATIVE; VITAMIN B COMPLEX;

ALUMINUM BLOOD LEVEL; ALUMINUM OVERLOAD; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD SAMPLING; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONTAMINATION; DRUG ELIMINATION; DRUG USE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; THERAPY EFFECT;

ALUMINUM; DRUG CONTAMINATION; HUMANS; KIDNEY FAILURE, CHRONIC; PHARMACEUTICAL PREPARATIONS; RENAL DIALYSIS;

EID: 65349156550     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn631     Document Type: Article

References (16)

1. Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis, 4th edn. Boston, MA: Little, Brown and Co., 2007
2. Persy VP, Behets GJ, Bervoets AR et al. Lanthanum: a safe phosphate binder. Semin Dial 2006; 19: 195-199
3. Storms LE, Chicella MF, Dice JE. Sevelamer therapy for pediatric end-stage renal disease. Pharmacotherapy 2006; 6: 410-413
4. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 2005; 16(Suppl 2): S107-S114
5. Kausz AT, Antonsen JE, Hercz G et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 1999; 34: 688-693
6. Gault PM, Allen KR, Newton KE. Plasma aluminium: still necessary for patients on renal dialysis? Ann Clin Biochem 2006; 43: 51-54
7. Jaffe JA, Liftman C, Glickman JD. Frequency of elevated serum aluminium levels in adult dialysis patients. Am J Kidney Dis 2005; 46: 316-319
8. Bohrer D, Bertagnolli DC, Oliveira SMR et al. Drugs as a hidden source of aluminium for chronic renal patients. Nephrol Dial Transplant2007; 22: 605-611
9. Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci 1989; 297: 9-11
10. Gomez M, Domingo JL, Llobet JM. Developmental toxicity evaluation of oral aluminum in rats: influence of citrate. Neurotoxicol Teratol1991; 13: 323-328
11. Coburn JW, Mischel MG, Goodman WG et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 1991; 17: 708-711
12. Taylor GA, Moore PB, Ferrier IN et al. Gastrointestinal absorption of aluminium and citrate in man. J Inorg Biochem 1998; 69: 165-169
13. Sherrard DJ. Aluminum-much ado about something. New Engl J Med 1991; 324: 558
14. Swaminathan S, High WA, Ranville J et al. Cardiac and vascular metal depositionwith high mortality in nephrogenic systemic fibrosis. Kidney Int 2008; 73: 1413-1418
15. Bohrer D, Nascimento PC, Pomblum SG. Deproteinization of blood serum by acid treatment and microwave irradiation for the determination of aluminium by electrothermal atomicabsorption spectrometry. J Anal At Spectrom 1998; 13: 635-639
16. Oliveira SMR, Bertagnolli DC, Bohrer D et al. Serum aluminium: influence of water and food consumed by patients with chronic renal insufficiency on regular hemodialysis treatment. J Bras Nefrol 2005; 27: 101-109